Successful use of etanercept in type I pityriasis rubra pilaris

Type I Pityriasis Rubra Pilaris: Upregulation of Tumor Necrosis Factor α and Response to Adalimumab Therapy

“…The reported therapies include retinoids, psoralen plus ultraviolet A phototherapy, and methotrexate. 13 More recently, there have been a number of case reports and letters documenting satisfactory clinical improvement with monotherapy of anti-TNF drugs (infliximab 1-5 or etanercept 7,8 ) in severe or refractory PRP patients, whereas our case and a recent report by Walling and Swick 14 demonstrated rapid and dramatic efficacy using adalimumab as a monotherapy for PRP.…”

Pityriasis Rubra Pilaris Responding Rapidly to Adalimumab

“…3 As with our patient, lipoatrophy was noted on both thighs and at the injection sites after 4 years of treatment, but it was preceded by tender and rubor plaques. To our knowledge, the first case of lipoatrophy after subcutaneous injection of interferon beta-1a in a patient with multiple sclerosis was reported in 2006.…”

“…3 In the Renaissance, Vesalius' Fabrica and Paracelsus' chemical doctrine refuted Galeni and opened the gates to the scientific revolution. The role of mercury and sulfur is linked to Paracelsus, who developed new theories about the origin of diseases, adding to the Hippocratic-Galenic humors: sulfur, mercury, and salt.…”

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

“…Of note, the first case of type III classic juvenile-onset PRP successfully treated with infliximab has recently been reported, 12 and the first two cases of type I PRP treated successfully with combination etanercept and acitretin therapy have emerged. 13,14 The T cell modulator efalizumab has been suggested to improve the disease in a 10-year-old boy unresponsible to multiple common therapies 15 but to exacerbate it in an adult patient. 16 In summary, the above listed cases with TNF-a inhibitors propose a significant response to anti-TNF-a therapy when used in combination therapy and/or in pretreated patients.…”